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Loss-of-function mutation V290M in the ligand-binding domain of
the peroxisome proliferator activated receptor γ (PPARγ) is asso-
ciated with a ligand resistance syndrome (PLRS), characterized by
partial lipodystrophy and severe insulin resistance. In this data
article we discuss an X-ray diffraction dataset that yielded the
structure of PPARγ LBD V290M mutant reﬁned at 2.3 Å resolution,
that allowed building of 3D model of the receptor mutant with
high conﬁdence and revealed continuous well-deﬁned electron
density for the partial agonist diclofenac bound to hydrophobic
pocket of the PPARγ. These structural data provide signiﬁcant
insights into molecular basis of PLRS caused by V290M mutation
and are correlated with the receptor disability of rosiglitazone
binding and increased afﬁnity for corepressors. Furthermore, our
structural evidence helps to explain clinical observations which
point out to a failure to restore receptor function by the treatment
with a full agonist of PPARγ, rosiglitazone.
& 2016 The Auhtors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
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acquiredAdvanced Light Source (ALS), beamline 5.0.1 - Lawrence Berkeley National
Laboratory (Berkeley, CA, USA)ata format PDB format text ﬁle. Binary structure factors in mtz format. Analyzed by
iMosﬂm, Phenix and Coot and Pymolxperimental
factorsPPARγ V290M LBD at 15 mg/mL mixed with 1 mM of sodium diclofenac on
ice and allowed to stand at 277 K overnight prior crystallization. Crystals
were soaked in a cryoprotectant containing the same reservoir solution
added with 15% (v/v) ethylene glycol and rapidly cooled in a gaseous nitro-
gen stream at 100 K for data collection.xperimental
featuresPPARγ LBD V290M mutant was crystallized by sitting drop vapor diffusion,
cooled to 100 K and subjected to synchrotron radiation from which X-ray dif-
fraction images were collected. The images were computationally analyzed to
index reﬂections and extract associated intensities. Molecular replacement
technique was used to obtain phase information. Final structure model was
obtained after several rounds of a combination of automated and manual
reﬁnement.ata source
locationBerkeley, CA, USAata accessibility Data is within this article. Protein coordinate data is publically available is the
RSCB Protein Database (http://www.rscb.org/) using the PDB: 4OJ4Value of the data
 PPARγ LBD V290M mutant [1] is one of the mutants associated with PPARγ Ligand Resistance
Syndrome [2–4]. People harboring this mutation do not respond to a treatment with full agonists
such as rosiglitazone. Structure provides explanation for the impairment of PPARγ function and
decreased afﬁnity to full agonists.
 Structure of PPARγ LBD V290M mutant in complex with diclofenac shows that partial agonists can
bind to PPARγ receptor mutants.
 Structure of PPARγ LBD V290M mutant may assist in designing of new compounds that have a
capacity to bind to the mutant receptor and might offer new possibilities of medical treatment for
patients harboring this mutation.1. Data
The present article provides details on crystallization, data collection and structure determination
of PPARγ V290M mutant (PDB: 4OJ4). We also describe the mutant receptor structure and how this
mutation could impair PPARγ function.2. Experimental design, materials and methods
2.1. Site directed mutagenesis, protein expression and puriﬁcation
Mutagenesis was performed using the PET28a vector containing PPARγ LBD nucleotide sequence.
The primer CATTATTCTCAGTGGAGACTGCCCAGGTTTGCTGAATGTG was used to substitute amino acid
residue valine 290 by methionine (V290M) using standard site-directed mutagenesis with the
QuickChange site-directed mutagenesis kit (Stratagene). The mutation V290M was veriﬁed by
sequencing. The plasmid pET28a(þ) (Novagen) encoding a human PPARγ V290M LBD fused in frame
to the C-terminus of a polyhistidine (His) tag was used to transform competent Escherichia coli strain
BL21 (DE3). The expression and puriﬁcation of PPARγ V290M LBD was performed as described [7].
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Several strategies were used to crystallize PPARγ V290M LBD by varying protein concentration (5–
18 mg/mL), temperature (277 and 291 K), crystallization techniques (hanging drop, sitting drop,
microbatch and seeding) and by addition of ligands (sodium diclofenac, luteolin, nonanoic acid,
rosiglitazone and troglitazone), detergents and additives (Hampton Research). The successful con-
ditions for crystallization were obtained using PPARγ V290M LBD at 15 mg/mL mixed with 1 mM of
sodium diclofenac (Sigma Aldrich) on ice and allowed to stand at 277 K overnight. The crystallization
screens were performed using a Mosquito (TTP LABtech) by sitting drop of 0.5 ml of protein complex
solution mixed with 0.5 ml precipitant solution and equilibrated against a 100 mL reservoir solution
from several commercial kits. Crystals were obtained with PEG 4000 30%, CaCl2 200 mM and HEPES
100 mM pH 7.5 (Kit PEG II, Qiagen). Before data collection, the crystals were soaked in a cryopro-
tectant containing the same reservoir solution added with 15% (v/v) ethylene glycol and rapidly
cooled in a gaseous nitrogen stream at 100 K. X-ray diffraction data were collected in the protein
crystallography beamline 5.0.1. of the Advanced Light Source (ALS) at Lawrence Berkeley National
Laboratory (Berkeley, CA, USA). Diffraction data were processed using MOSLFM [11] and scaled with
SCALA from the CCP4 program suite [12]. The structure was determined by molecular replacement
using the program PHASER from CCP4 Packages and the PPARγ LBD structure (PDB: 3SZ1) as a model
removing H12, in which mutation V290M is located. The programs PHENIX and COOT were used to
alternately run cycles of reﬁnement and model building [13,14].
We crystallize the mutant PPARγ LBD with an anti-inﬂammatory compound that behaves as a
PPARγ partial agonist [5]. The X-ray diffraction dataset for PPARγ V290M mutant consist of 360
diffraction images that were collected at 0.5° rotation of the crystal giving 180° of diffraction data. The
diffractions spots are clean sharp and show a single lattice. There is also an evidence of crystalline
water (ice) formation (Fig. 1).
The PPARγ V290M mutant crystals belong to the space group P43212 with the unit cell dimensions
a¼b¼60.04 Å, c¼161.19 Å and diffracted to 2.3 Å resolution. The 12,961 unique reﬂections were
measured with an overall redundancy of 7.2. All data processing statistics indicate a high quality of
the dataset (Table 1). After molecular replacement and several rounds of intercalated automated
reﬁnement and manual model building, the PPARγ V290M crystal structure consisting of 2105 non-
hydrogen atoms was built. The structure was reﬁned to R-work¼21.94 %, R-free¼28.37% and has an
average B-factor of 47.48 Å2. Table 1 summarizes the ﬁnal data processing and reﬁnement statistics.Fig. 1. Crystals and X-ray diffraction image from the PPARγ V290M mutant dataset collected at (ALS), beamline 5.0.1.
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2.3.1. Electron density map and diclofenac binding site
A single PPARγ LBD forms the asymmetric unit of this 2.3 Å crystal structure, which is different
from most other PPARγ structures that frequently display two juxtaposed LBDs (A and B subunits) in
the asymmetric unit, even though in the present PPARγ V290M structure the dimeric arrangement is
realized by the interaction with a symmetric related monomer. The PPARγ V290M LBD adopts
standard NR fold and consists of 12 α-helices that form the classic three-layered antiparallel β-helical
sandwich fold with a small four-stranded β-sheets [6,7] (Fig. 2). The electron density was easily
interpretable and 2fo–fc map where diclofenac and the residue 290 were omitted showed strong
density corresponding to the mutant residue methionine and the presence of diclofenac at the
binding pocket. Diclofenac adopts a binding mode that resembles that of other partial agonists, lying
in a north-south orientation close to helix 3 and the β-sheets, in a similar position described for the
wild type receptor [5]. The only major differences between previous structures of the wild type PPARγ
with agonists and partial agonists and the mutant PPARγ LBD were related to helix H12 position and
we therefore will focus upon this particular aspect of the structure in our further analysis.
2.4. Crystal packing and structural changes
Loss-of-function mutation V290 M in the ligand-binding domain of PPARγ is associated with a
syndrome characterized by partial lipodystrophy and severe insulin resistance [1]. In the structure we
describe here, H12 protrudes from the V290 M mutant receptor surface at almost 90o angle (Fig. 2
inset). This is different from the standard active conformation typiﬁed by a PPARγ structure with
rosiglitazone and the coactivator SRC1 peptide bound to AF-2, where H12 packs against the H3 and
H5 to complete the coactivator binding surface (PDB: 2PRG) [6] (Fig. 3A). It is likely that steric clashes
between the methionine substituent and H12 are responsible for altered H12 position andTable 1
X-ray crystallographic data collection and reﬁnement statistics.
Data collection Reﬁnement
Source APS 5.0.1 Resolution 48.19–2.3 (2.36–2.3)
Wavelength 0.999 A° Reﬂections used 12210
Space group P43212 Reﬂections for R-free 643
Unit cell parameters Non-hydrogen atoms 2105
a(A°) ¼ b (A°) 60.04 Protein 2026
c(A°) 161.19 Diclofenac/ Calcium 21
Molecules in the ASU 1 Water 58
Resolution (A°) 56.26-2.3 (2.42-2.3) Rfactorc (%) 21.94
Unique reﬂections 12,961 (1,950) Rfreed (%) 28.37
Redundancy 7.2 (7.6) rmsd bond lenghts (A°) 0.013
Completeness (%) 93.2 (100) rmsd of bond angles (°) 1.638
Rsymb 0.152 (0.625) Average B-factor (A
°2) 47.48
oI4 /oσ(I)4 7.4 (2.80) Ramachandran outliers 1
Wilson B-factor (A°2) 36.3 Molprobity score 1.79 (96%)
PDB code PDB: 4OJ4
a Values in parameters refer to the last resolution shell.
b Rsym:
P
hkl,j (|Ihkl–o Ihkl4 |)/
P
hkl,j Ihkl, where o Ihkl4 is the average intensity for a set of j symmetry-related
reﬂections, and %.
c Rfactor:
P
hkl (||Fo|–|Fc||)/
P
hkl |Fo|,where Fo is the observed structure factor amplitude, and Fc is the calculated structure factor
amplitude.
d Rfree:
P
hkl,T(||Fo|–|Fc||)/
P
hkl |Fo|, where a test set, T (5% of data), is omitted from the reﬁnement.
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hydrophobic interactions with H12 H466, L468 and L469 (Fig. 3B). The bulky side-chain of methionine
(Fig. 3C) would clash with the L469 side-chain, preventing H12 closure. Additionally, L469 contributes
to the accommodation of the polar head of TZDs by hydrophobic interactions and Y473 makes a
hydrogen bond with the nitrogen of TZDs (Fig. 3C). Thus, it is also likely that blockade of H12 closure
will disrupt interactions with rosiglitazone and other TZDs and will impair TZD-dependent stabili-
zation of the domain.
It is likely that aberrant H12 position in the PPARγV290M mutant would affect recruitment of
coactivators. Correct H12 position is important for binding of short LxxLL motifs present in coacti-
vators such as SRC1 and CBP [8]. Agonists stabilize H12 to form a hydrophobic cleft that docks Leu
residues of LxxLL motif and also positions H12 E471 to complete a charge clamp that helps to anchor
the coactivator peptide via interactions with the helix dipole [6]. Superimposition of coactivator
peptide SRC1 from structure PDB: 2PRG (data not shown), reveals clashes between the coactivator
lysine and H12 from the mutant receptor suggesting that coactivator binding would be precluded in
this conformation. Besides this, the destabilization of H12 caused by mutation V290M could also
impair binding and activity of other agonists that interact with H12, such as NSAIDS [5]. However, it
was shown that some tyrosine-based (TA) receptor agonists can rescue mutant receptor function [9].
TAs (e.g. farglitazar) corrected defects in ligand binding and coactivator recruitment by natural
dominant negative PPAR mutants (V290M and P467L), restoring transcriptional function comparableig. 2. (A) Crystal structure of PPARγ LBD V290M mutant. H12 is colored in blue and β-sheet in orange (B) Omit map 2Fo–Fc is
hown in a contour of 1.0 σ for the region around methionine M290 (green, stick ball). H12 is colored in blue. (C) Omit map 2Fo–
c is shown in a contour of 1.0 σ for the diclofenac (pink, stick ball). Residues that interact with diclofenac are shown as sticks
nd β-sheet in orange.
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dominant-negative inhibition was achieved with TA than TZD agonists, that could be explained
because farglitazar makes more extensive contacts than rosiglitazone within the ligand-binding
pocket, to stabilize helix 12, facilitating corepressor release and transcriptional activation [9].
PPARγ usually crystallizes in the C2 space group with two LBDs in the asymmetric unit; an A-
subunit that adopts active conformation irrespective of the presence and type of ligand (agonist,
partial agonist) and a B-subunit that adopts an inactive conformation with H12 displaced from the
body of the domain. Novel H12 position observed in the present PPARγV290M structure also dif-
fered from the wild type PPARγ B subunit (Fig. 4B). Here, however, differences in H12 position could
partly reﬂect inﬂuences of crystal packing. We compared H12 of our structure with other four
structures that belong to the same space group P43212 (PDB: 3BCU, PDB: 3PRG, PDB: 3R5N, and
PDB: 4XLD (Fig. 4A). For the PPARγV290M mutant, H12 docks against its counterpart in the sym-
metric equivalent neighboring monomer (Fig. 4C), whereas H12 from the wild type PPARγ B subunit
docks into the AF-2 site of the A subunit of the neighboring dimer. Unusual H12 position of PPARγ
was also detected in the structure of the mutant F360L (PDB: 4L98), associated with familial partial
lipodystrophy, showing a similar interaction between H12 facing monomers and was attributed to
crystal packing [10] .Fig. 3. Comparisons of the crystal structures PPARγ LBD V290M (PDB: 4OJ4) and 2PRG structures (Diclofenac from PDB: 4OJ4
was omitted for clarity) (A). Valine 290 is an important residue for correct positioning of H12 and make hydrophobic inter-
actions with residues L468, L469 and H466. Y473 from H12 makes a hydrogen bond with rosiglitazone, stabilizing this helix in
an active conformation (B). Methionine M290 is a bulky residue than valine and cause clashes with L469, dislocating H12 and
preventing its closure. H12 from PPARγ LBD with rosiglitazone (pink, stick ball) (PDB: 2PRG) is shown in red and H12 from
mutant V290M structure is shown in blue. (C) H12 from PDB: 2PRG is shown in red and H12 from V290M structure (PDB:4OJ4)
is show in blue. Rosiglitazone from PDB: 2PRG is shown in pink (stick ball). Residues L469 and M290 are shown as dots and
represent Van der Waals interactions.
Fig. 4. (A) Superimposition of crystal structure of the mutant V290M (PDB: 4OJ4, H12, blue) with structures 3BCU (magenta),
3PRG (orange), 3R5N (red), and 4XLD (yellow) showing that the H12 in the V290M adopts a different conformation in com-
parison of active conformation found in the structures crystallized in the same space group P43212. (B) Superimposition of
crystal structure of the mutant V290M (PDB: 4OJ4, H12, blue) with that of the chain B in the complex PPARγ/luteolin
(PDB3SZ1), showing H12 (dark green) indifferent inactive conformation. Both structures show inactive conformation of H12
and both are due to crystal packing (C) Analysis of the crystal packing of the mutant V290M showing that the conformation
adopted by H12 occurs because hydrogen bonds between Q470 and Y473 with the H12 of symmetric related monomer.
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